Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lecanemab Hits PIII Mark with 27% Cut in Clinical Decline, Eisai Set for Submissions by March-End
September 29, 2022
- Evusheld Can Fulfill Immunodeficient Patients’ Needs: AstraZeneca Japan VP
September 28, 2022
- Sumitomo Appeals to US Court to Overturn Dismissal of Latuda’s Use Patent
September 28, 2022
- Janssen’s CAR-T Therapy Carvykti Approved in Japan
September 27, 2022
- Promotions via In-Hospital Seminars, Webinars, Internet Channels Log Two-Digit Growth in August: Intage
September 27, 2022
- Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
- Hospira Barred from Launching Lexiscan Generic until Oct. 5: Astellas
September 27, 2022
- Healios Licenses Non-Exclusive Rights for iPSC Line to RxCell
September 26, 2022
- Towa Prevails in IP High Court Ruling for Livalo Damage Suit, Kowa Mulls Next Step
September 22, 2022
- Pfizer Japan to Discontinue Ibrance’s Capsule Products
September 22, 2022
- Janssen Aims to Rank Among Top 3 Drug Makers in Japan by 2024: Local Chief
September 22, 2022
- UCB’s Epilepsy Drug Brivaracetam Hits PIII Goal, Japan Submission Eyed in 2023
September 21, 2022
- Otsuka’s Lupus Nephritis Med Lupkynis Wins European Greenlight
September 21, 2022
- Takeda’s CMV Drug Maribavir Snags EU Panel Backing
September 21, 2022
- Boehringer Ingelheim Revamping Biz Sites in Japan to Spur Communications among Drug Reps
September 20, 2022
- Daiichi Sankyo Apologizes for Arrest of Employee
September 20, 2022
- Shionogi Eyes EUA of COVID Pill in South Korea via Sublicense to Local Firm
September 20, 2022
- Asahi Kasei Bags Japan Commercial Rights for Two Sobi Treatments
September 16, 2022
- Kyowa Kirin Seeks Palmoplantar Pustulosis Nod for Lumicef in Japan
September 16, 2022
- Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
September 16, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…